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Abstract
Introduction: Activation of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK)
pathways results in anti-estrogen resistance in vitro, but a biomarker with clinical validity to predict intrinsic resistance
has not been identified. In metastatic breast cancer patients with previous exposure to endocrine therapy, the
addition of a mammalian target of rapamycine (mTOR) inhibitor has been shown to be beneficial. Whether or not
patients on adjuvant endocrine treatment might benefit from these drugs is currently unclear. A biomarker that
predicts intrinsic resistance could potentially be used as companion diagnostic in this setting. We tested the
clinical validity of different downstream-activated proteins in the PI3K and/or MAPK pathways to predict intrinsic
tamoxifen resistance in postmenopausal primary breast cancer patients.
Methods: We recollected primary tumor tissue from patients who participated in a randomized trial of adjuvant
tamoxifen (1–3 years) versus observation. After constructing a tissue micro-array, cores from 563 estrogen receptor α
positive were immunostained for p-AKT(Thr308), p-AKT(Ser473), p-mTOR, p-p706SK and p-ERK1/2. Cox proportional
hazard models for recurrence free interval were used to assess hazard ratios and interactions between these markers
and tamoxifen treatment efficacy.
Results: Interactions were identified between tamoxifen and p-AKT(Thr308), p-mTOR, p-p70S6K and p-ERK1/2. Applying
a conservative level of significance, p-p70S6K remained significantly associated with tamoxifen resistance. Patients with
p-p70S6K negative tumors derived significant benefit from tamoxifen (HR 0.24, P < 0.0001), while patients whose
tumor did express p-p70S6K did not (HR = 1.02, P =0.95), P for interaction 0.004. In systemically untreated breast
cancer patients, p-p70S6K was associated with a decreased risk for recurrence.
Conclusions: Patients whose tumor expresses p-p70S6K, as a marker of downstream PI3K and/or MAPK pathway
activation, have a favorable prognosis, but do not benefit from adjuvant tamoxifen. A potential benefit from
inhibitors of the PI3K/Akt/mTOR pathway in these patients needs to be further explored.
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Introduction
Activation of the mitogen-activated protein kinase
(MAPK) and phosphatidylinositol-3-kinase (PI3K) path-
ways confers anti-estrogen resistance in vitro [1-3].
Apart from activation by the canonical pathway drivers
(PIK3CA mutations [4], loss of PTEN [5] or overexpres-
sion of growth factor receptors such as human epider-
mal growth factor receptor 2 (HER2) [6] and insulin like
growth factor 1 receptor [7]), in vitro data have shown
that the PI3K pathway can also be activated in response
to estrogen depletion. This results in acquired hormone-
resistant breast cancer cells that are sensitive to PI3K/
mammalian target of rapamycine (mTOR) inhibition [8].
These preclinical data support the clinical observation
that estrogen receptor alpha (ERα)-positive metastatic
breast cancer patients with prior exposure to aromatase
inhibitors derive substantial benefit from the addition of
an mTOR inhibitor [9]. Whether or not patients who
are primarily resistant to adjuvant endocrine therapy
might benefit from PI3K and/or MAPK pathway inhib-
ition remains to be defined. A biomarker of an activated
PI3K and/or MAPK pathway with clinical validity to pre-
dict resistance in the adjuvant setting has not been iden-
tified [10], but could potentially be used as a companion
diagnostic for non-ERα-targeted drugs, such as an
mTOR inhibitor.
Several canonical pathway drivers, such as PIK3CA
mutations [11,12], loss of PTEN [12], and HER2 [13],
have been studied for their validity to predict resistance.
However, none of these drivers significantly predicts lack
of benefit from endocrine therapy. An important issue
to be considered is that the presence of these drivers in
clinical samples may not necessarily result in high acti-
vation of downstream proteins [12,14]. In vitro, PI3K
pathway activation leads to phosphorylation of AKT and
subsequently of mTOR and p70S6K [10]. Phosphoryl-
ation of extracellular signal-regulated kinase (ERK)1/2 is
a result of MAPK pathway activation [15] and mediates
activation of p70S6K [16]. However, relatively moderate
activation of the PI3K pathway was seen in tumors with
a PIK3CA exon 20 mutation-associated gene signature
[14]. In addition, in a large series of primary breast can-
cer tumors, reverse-phase protein analysis did not show
activation of the typical downstream proteins in the
PI3K pathway in PIK3CA mutated luminal A tumors
[17]. The activation status of downstream proteins rather
than the presence or absence of a canonical driver there-
fore probably ultimately defines anti-estrogen sensitivity
in breast cancer patients.
We hypothesized that activated proteins downstream
in the PI3K and/or MAPK kinase pathways could poten-
tially be used as a marker that separates patients who
are likely to benefit from adjuvant tamoxifen treatment
from those who are primarily resistant to this drug. The
aim of our study was therefore to investigate the predict-
ive value of different downstream activated proteins in
the PI3K and/or MAPK pathways in a large series of
ERα-positive postmenopausal breast cancer patients ran-
domized between adjuvant tamoxifen versus no systemic
treatment.
Methods
Patients and materials
We have recollected primary tumor tissue blocks from
stage I to III postmenopausal breast cancer patients
who were randomized (2:1) between 1 year of tamoxi-
fen (30 mg/day) versus no adjuvant therapy (IKA trial,
1982 to 1994) [18,19]. Study data were part of the Oxford
meta-analysis [20]. After 1989, based on two interim
analyses showing a significant improvement in recurrence-
free survival in lymph node-positive patients, node-positive
patients in this trial skipped the first randomization
and all received 1 year of tamoxifen. After 1 year a sec-
ond randomization was performed to receive another 2
years of tamoxifen or to stop further treatment. In total,
1,662 patients were included. None of these patients re-
ceived adjuvant chemotherapy. The patient characteris-
tics and clinical outcome of the original study group
(1,662 patients) have been presented elsewhere [19].
Sufficient tumor material was available for 739 pa-
tients, who did not differ in prognostic factors from the
total group (Table S1 in Additional file 1). After revision
of ERα status as assessed with immunohistochemistry
(IHC), a total of 563 ERα-positive tumors were used for
subsequent analysis. We used a cutoff value ≥10% of
positive tumor cells for ERα positivity, since this is com-
mon practice in the Netherlands and also this would
avoid the potential inclusion of basal-like tumors [21] in
our analysis. The original trial was approved by the cen-
tral ethics committee of the Netherlands Cancer Insti-
tute and informed consent was obtained from all study
participants. For this retrospective translational study,
no additional consent was required according to Dutch
legislation [22] since the use of archival pathology left-
over material does not interfere with patient care.
Tumor tissue was handled according to the Dutch code
of conduct for dealing responsibly with human tissue in
the context of health research [23].
Immunohistochemistry
Tissue microarrays (TMAs) were constructed using
formalin-fixed paraffin-embedded tumor blocks. A total
of three (0.6 mm) cores per tumor were embedded in
the TMAs that were stained for ERα, progesterone re-
ceptor (PgR) and HER2. ERα and PgR were considered
positive when ≥10% of invasive cells showed nuclear re-
activity. HER2 was considered positive when membran-
ous staining was DAKO score 3 [24]. In the case of
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DAKO score 2, chromogenic in situ hybridization was
performed. For tumors without sufficient cores in the
TMA, whole slides were cut and assessed for ERα (n =
60), PgR (n = 55) and HER2 (n = 36). The tumor grade was
scored on a hematoxylin and eosin-stained slide using the
modified Bloom–Richardson score [25].
Antibodies used for immunohistochemistry of down-
stream phosphorylated (p) proteins are shown in Table S2
in Additional file 1. For p-AKT(Ser473), antigen retrieval
was performed using citrate buffer and slides were incu-
bated overnight with antibody (dilution 1:50). All other
phospho-protein stainings (p-AKT(Thr308), p-mTOR,
p-ERK1/2 and p-p70S6K) were performed using a stan-
dardized protocol on the Ventana Benchmark® Ultra system
(Ventana Medical Systems, Tucson, USA). To ensure
phospho-specificity of the antibodies, for each antibody a
test TMA containing positive cores was dephosphorylated
by λ-phosphatase before staining, resulting in disappear-
ance of the positive staining (Figure S1 in Additional file 1).
Cytoplasmic intensity (0 to 3) was assessed for p-AKT
(Ser473), p-AKT(Thr308) and p-p70S6K. The percentage
of tumor cells with submembranous staining was scored
for p-mTOR, and the proportion of positive nuclei was
scored for p-ERK1/2. For each staining, one of the
TMAs was quantified independently in a blinded man-
ner by a second observer to calculate inter-observer
variability. For further analyses, we used the scores pro-
duced by the first observer (MO).
Since the stability of phospho-proteins is a matter of de-
bate [26], we tested whether the relative age of tumor sam-
ples (divided in quartiles) was associated with quantitative
phospho-protein staining for each of these markers. In
addition, to test for a possible effect of different fixation
procedures, we tested whether the inclusion center was as-
sociated with differences in quantitative phospho-protein
expression.
Statistical analysis
The recurrence-free interval was defined as the time
from the date of first randomization until the occurrence
of a local, regional or distant recurrence or breast
cancer-specific death [27]. Since a secondary contralat-
eral breast tumor cannot be inferred from the molecular
make-up of the primary tumor, while the other type of
events can be inferred in relation to tamoxifen resistance
of the primary tumor, this was not considered an event
and these patients were censored at the date of this oc-
currence. The association between expression of down-
stream activated proteins and known prognostic factors
was tested using Fisher’s exact test.
We hypothesized that high expression of downstream
activated proteins is associated with tamoxifen resistance.
Our primary analysis was therefore to test whether tam-
oxifen benefit was dependent on any of the downstream
activated proteins in the PI3K and/or MAPK pathway. We
analyzed these markers as a binary factor, using the me-
dian level as the cutoff value. Adjusted Cox proportional
hazard regression analyses were performed including an
interaction variable. Covariates included age (≥65 vs. <65),
grade (grade 3 vs. grade 1 to 2), tumor size (T3 to T4 vs.
T1 to T2), HER2 status (positive vs. negative), and PgR sta-
tus (positive vs. negative). All survival analyses were strati-
fied for nodal status. Owing to the multiple co-primary
endpoints of this study, we apply a more conservative level
of significance (α = 0.01) when assessing the interactions.
Further exploratory analyses examined tamoxifen bene-
fit when the markers were implemented as continuous lin-
ear variables. For those continuous linear variables that
showed an interaction with tamoxifen treatment, we ex-
plored which level of dichotomization best predicted tam-
oxifen benefit, by comparing Akaike’s information criteria
of the Cox proportional hazards models for all possible
cutoff values. In addition, based on knowledge derived
from preclinical studies [1,3], we explored whether a
composed variable of either high p-ERK1/2 or high
p-mTOR – indicating the activation of either the MAPK
pathway or the PI3K pathway – was associated with tam-
oxifen resistance. To assess the prognostic value of the
phospho-proteins, we analyzed their putative prognostic
potential in the subgroup of patients who were random-
ized to the control arm. The reason why we did not use all
patients and corrected for tamoxifen treatment is that this
correction would assume that all ERα-positive breast can-
cer patients would derive similar benefit from tamoxifen.
Since the phospho-protein might be associated with tam-
oxifen resistance, simply correcting for the assumed tam-
oxifen benefit without a correction for a potential
interaction between treatment and phospho-protein could
bias the analysis for prognostic potential. Survival curves
were constructed using the Kaplan–Meier method. This
study complied with reporting recommendations for
tumor marker prognostic studies (REMARK) criteria [28]
as outlined in Table S3 in Additional file 1.
Results
Association of downstream activated proteins in the PI3K
and/or MAPK pathways with clinico-pathological factors
The inter-observer variability analyzed using the (weighted)
Cohen’s kappa coefficient is depicted in Table S4 in
Additional file 1. Figure S2 in Additional file 1 shows
the number of evaluable cases for each downstream
protein. We did not find a significant difference in me-
dian phospho-protein expression and relative age of
tumor samples (Figure S3a,b,c,d,e in Additional file 1).
Median phospho-protein expression was not signifi-
cantly different among inclusion centers (Figure S4a,b,
c,d,e in Additional file 1).
Beelen et al. Breast Cancer Research 2014, 16:R6 Page 3 of 10
http://breast-cancer-research.com/content/16/1/R6
We did not find a significant association between
p-p70S6K and any of the known clinico-pathological
variables (Table 1). Significant associations were found
between p-p70S6K and all other downstream activated
proteins (Table 1). The association between other down-
stream activated proteins and known prognostic variables
is shown in Table S5 in Additional file 1. High p-mTOR
and positive p-ERK1/2 staining were both associated with
a positive PgR status and low tumor grade. In addition,
high expression of p-AKT(Ser473) was associated with a
positive PgR status.
Downstream activated proteins in the PI3K and/or MAPK
pathways predict resistance to tamoxifen
In the total group of ERα-positive patients (n = 563), a
total of 132 recurrence-free interval events occurred
(Table S6 in Additional file 1). The number of patients
in each treatment arm pre and post interim analysis is
shown in Figure S5 in Additional file 1. The median
follow-up of patients without a recurrence event is 7.8
years. When stratified by nodal status, the hazard ratio
(HR) for tamoxifen versus control in this cohort was 0.54
(95% confidence interval (CI) = 0.36 to 0.83, P = 0.004). In
our primary analysis, using the median expression levels
as the cutoff value for a binary factor, we did not find a
significant interaction between either p-AKT(Ser473) or
p-mTOR and tamoxifen. In addition, the interactions
between both p-AKT(Thr308) and p-ERK1/2 and tam-
oxifen were nonsignificant (adjusted P for interaction
0.09 and 0.06 respectively) (Table 2). However, we ob-
served a significant interaction for p-p70S6K with tamoxi-
fen (P = 0.004). Patients whose tumor did not express
p-p70S6K derived significant benefit from tamoxifen
(HR = 0.24, 95% CI = 0.12 to 0.47, P < 0.0001), while pa-
tients whose tumor did express p-p70S6K had no benefit
(multivariate HR = 1.02, 95% CI = 0.48 to 2.21, P = 0.95)
(Figure 1A; Table S7 in Additional file 1). Performing the
same analysis using a 1% cutoff value for ERα positivity
added four extra patients and did not substantially change
these results (data not shown).
In our exploratory analyses, analyzing the expression
of downstream activated proteins as a continuous vari-
able, we observed an interaction with tamoxifen for
p-AKT(Thr308) (adjusted P = 0.03), p-mTOR (adjusted
P = 0.03) as well as p-p70S6K (adjusted P = 0.006)
(Table S8 in Additional file 1). Examining Akaike’s in-
formation criteria values indicated that a dichotomiza-
tion of p-mTOR submembranous staining into <60%
and ≥60% provided the best fit to the data (Table S9
and Figure S6 in Additional file 1). For p-AKT(Thr308),
p-ERK1/2 and p-p70S6K, a dichotomization in any posi-
tive versus negative staining (which corresponded with di-
chotomization with median expression levels as the cutoff
values) provided the best fit to the data (Tables S10,S11
and Figures S7,S8 in Additional file 1). Tables S12,S13,S14,
S15 in Additional file 1 present the distribution of known
prognostic factors over the treatment arms both for pa-
tients who were positive and for patients who were nega-
tive for these markers.
Based on preclinical knowledge that p-ERK1/2 and
p-mTOR represent activation of, respectively, the MAPK
pathway and the PI3K pathway, we explored the inter-
action with tamoxifen for the combination of these
markers. Patients with a tumor that expressed either high
p-mTOR or positive p-ERK1/2 protein did not benefit
from tamoxifen (adjusted HR = 1.00, 95% CI = 0.48 to
Table 1 Associations between p-p70S6K and clinico-
pathological variables as well as other PI3K and/or MAPK
pathway proteins
p-p70S6K (n = 438)
Negative
(n = 188)
Positive
(n = 250)
P value
Treatment No tamoxifen 40 (21) 55 (22) 0.92a
Tamoxifen 1 year 89 (47) 113 (45)
Tamoxifen 3 years 59 (31) 82 (33)
Age <65 82 (44) 128 (51) 0.12b
≥65 106 (56) 122 (49)
Lymph node Negative 92 (49) 141 (56) 0.12b
Positive 96 (51) 109 (44)
T stage T1 to T2 167 (89) 221 (88) 1.00b
T3 to T4 21 (11) 29 (12)
Grade Grade 1 to 2 123 (65) 153 (61) 0.37b
Grade 3 65 (35) 97 (39)
Progesterone
receptor
Negative 98 (52) 111 (44) 0.10b
Positive 88 (47) 139 (56)
Missing 2 (1) 0 (0)
HER2 Negative 168 (89) 223 (89) 0.17b
Positive 12 (6) 26 (10)
Missing 8 (4) 1 (0)
p-AKT(Ser473)c Low (0 to 1) 109 (71) 53 (24) <0.0001b
High (2 to 3) 44 (29) 172 (76)
p-AKT(Thr308)c Negative 143 (81) 87 (36) <0.0001b
Positive 34 (20) 153 (64)
p-mTORc Low (0 to 59%) 156 (87) 176 (73) 0.0003b
High (≥60%) 23 (13) 66 (27)
p-ERK1/2c Negative 114 (65) 61 (26) <0.0001b
Positive 61 (35) 177 (74)
Data presented as n (%). ERK, extracellular signal-regulated kinase; HER2,
human epidermal growth factor receptor 2; MAPK, mitogen-activated protein
kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-
kinase; p, phosphorylated. aLinear by linear test. bFisher’s exact test (analysis
based on cases without missing values). cMissing data not shown.
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2.08, P = 1.00), while patients whose tumor was nega-
tive for these two markers did derive significant benefit
(adjusted HR = 0.25, 95% CI = 0.13 to 0.48, P < 0.0001)
(P for interaction = 0.004) (Figure 1B; Table S16 in
Additional file 1).
Downstream activated proteins in the PI3K and/or MAPK
pathways are associated with good prognosis in the
absence of adjuvant systemic treatment
When systemically untreated breast cancer patients were di-
chotomized according to p-AKT(Ser473), p-AKT(Thr308),
p-mTOR or p-p70S6K status, the group that was posi-
tive for the marker (dichotomized according to Akaike’s
information criteria) exhibited a decreased risk for re-
currence compared with patients whose tumor had no
or low expression of the marker (Figure 2 and Table 3;
Tables S17,S18,S19,S20 in Additional file 1). A similar
trend was seen for patients whose tumor did express
p-ERK1/2 (P = 0.14). Hierarchical clustering of the down-
stream activated proteins in the PI3K and/or MAPK path-
way is shown in Figure 3.
Discussion
In this retrospective analysis of tumor samples from
ERα-positive postmenopausal breast cancer patients, we
have shown the clinical validity of p-p70S6K, as a marker
of PI3K and/or MAPK pathway activation, to predict
adjuvant tamoxifen resistance. Patients whose tumor
expressed p-p70S6K did not benefit from adjuvant tam-
oxifen, confirming previous in vitro findings [1,2].
We are aware of the discussion that the use of phos-
pho-specific antibodies for IHC may be challenging,
since preanalytic variables (such as fixation technique and
duration) may critically affect the signal [26]. Although
we did not observe an association between phospho-
protein expression and either tumor size, inclusion
center or relative age of the tumor sample and con-
firmed the phospho-specificity of the antibodies, we
cannot exclude that unknown preanalytic variables
might have affected the results of IHC. Nevertheless,
since these unknown variables would have affected both
tumor samples from control patients as well as
tamoxifen-treated patients, the observed predictive value
of p-p70S6K markers is probably not biased by these
preanalytic variables. Unlike others [29,30], we have
used automatic immunostainings to improve robustness
and reproducibility of these IHC-based tests. Neverthe-
less, the visual interpretation of IHC-based tests is still
a subjective, time-consuming and variable process,
with an inherent intra-observer and inter-observer
variability [31,32]. The technical validity of IHC-based
tests may therefore be further improved by image ana-
lysis applications on digital slides [33]. We deemed a
direct comparison of the observed frequencies of breast
cancers scoring positive for the downstream-activated
proteins analyzed with those observed in other studies
[30,34,35] not to be appropriate due to differences in
study population, antibodies and staining techniques as
well as interpretation of these stainings.
Very few studies have tested the predictive validity of
downstream-activated proteins in the PI3K and/or
MAPK pathway in the context of a randomized clinical
trial. Perez-Tenorio and colleagues observed a decreased
benefit from tamoxifen only in those patients with
PIK3CA mutations who also expressed AKT activation
[12], but the test for interaction was not significant. In a
subgroup analysis of ERα-positive and PgR-positive pa-
tients, Bostner and colleagues recently observed a re-
duced benefit from tamoxifen in those patients whose
tumor expressed high p-mTOR [29]. These results sup-
port our data and suggest that downstream activated
proteins have a superior clinical validity to predict
Table 2 Adjusted hazard ratios and tests for interaction between PI3K and/or MAPK pathway markers and tamoxifen
Variable level Adjusted hazard ratioa for tamoxifen
versus control (95% confidence interval)
Adjusted P value for interaction
p-AKT (Ser473) Below median (0 to 1) 0.34 (0.17 to 0.69) 0.16
Above median (2 to 3) 0.68 (0.33 to 1.38)
p-AKT (Thr308) Below median (0) 0.42 (0.24 to 0.74) 0.09
Above median (1 to 3) 1.03 (0.43 to 2.50)
p-mTOR Below median (0 to 20%) 0.41 (0.23 to 0.71) 0.25
Above median (21 to 100%) 0.74 (0.31 to 1.76)
p-ERK1/2 Below median (0) 0.34 (0.18 to 0.63) 0.06
Above median (1 to 100%) 0.87 (0.40 to 1.87)
p-p70S6K Below median (0) 0.24 (0.13 to 0.47) 0.004
Above median (1 to 3) 1.02 (0.48 to 2.21)
ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase;
p, phosphorylated. aRecurrence-free interval survival. Models were adjusted for age, T stage, grade, progesterone receptor status and human epidermal growth
factor receptor 2 status. Models were stratified for nodal status.
Beelen et al. Breast Cancer Research 2014, 16:R6 Page 5 of 10
http://breast-cancer-research.com/content/16/1/R6
endocrine resistance compared with the presence or ab-
sence of a pathway driver [36]. The strength of our study
is that we pre-specified the cutoff value (median expres-
sion level) that was used for the primary analysis of the
putative marker as a binary factor. In addition, we tested
the markers as continuous linear variables and used
Aikake’s information criteria to define the optimal cutoff,
which coincided with the median for most putative bio-
markers. p-p70S6K (as a marker of activation of either
the PI3K pathway and/or the MAPK pathway) was the
only significant marker according to our conservative
definition of significance, although most of the other
downstream activated proteins showed a similar trend.
In addition, we found a significant interaction for the
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Figure 1 Kaplan–Meier survival analysis according to tamoxifen treatment and PI3K and/or MAPK pathway marker. (A) Kaplan–Meier
survival analysis according to tamoxifen treatment and p-p70S6K expression: recurrence-free interval according to tamoxifen treatment in patients
whose tumors do not express p-p70S6K (left) and patients whose tumors do express p-p70S6K (right). (B) Kaplan–Meier survival analysis according
to tamoxifen treatment and p-mTOR and p-ERK1/2 expression: recurrence-free interval according to tamoxifen treatment in patients whose
tumors do express low p-mTOR and are p-ERK1/2 negative (left) and in patients whose tumors do express p-ERK1/2 and/or express high p-mTOR
(right). Contr, control; ERK, extracellular signal-regulated kinase; HR, hazard ratio; MAPK, mitogen-activated protein kinase; mTOR, mammalian target
of rapamycine; PI3K, phosphatidylinositol-3-kinase; p, phosphorylated; TAM, tamoxifen.
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composed variable of either high p-ERK1/2 and/or
p-mTOR expression, representing activated MAPK and
PI3K pathways, respectively.
In our study, interestingly, most of the markers of
PI3K and/or MAPK activation were associated with a fa-
vorable prognosis in the absence of systemic treatment.
Although an association with low-grade and positive
PgR status was shown, the favorable outcome was inde-
pendent of these factors in multivariate analysis. The
question arises of why these tumors have a favorable
prognosis. Although others have studied the association
of these markers with prognosis in series of patients
treated with endocrine therapy [8,30,37], none of these
studies discerned prognosis from prediction. In case a
putative biomarker under investigation results in a
reduced treatment efficacy, this would cancel out a po-
tential prognostic effect if the biomarker is analyzed in
series of patients who are all treated with the drug [10].
A direct comparison between our data and these studies
is therefore not possible.
Our study has several limitations. First of all, for retro-
spective biomarker analysis we could only use the sub-
group of 563 ERα-positive patients from whom sufficient
tumor material was available. However, this subgroup did
not differ from the total study population. Furthermore,
the duration of tamoxifen therapy differs from the current
duration of at least 5 years. However, we anticipate that
the relative effects of the biomarkers analyzed in this study
will be similar for shorter and longer duration of endo-
crine therapy. The patients in our study randomized to
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Figure 2 Kaplan–Meier survival analyses in control patients according to p-p70S6K and p-mTOR. Kaplan–Meier survival analysis for
recurrence-free interval according to (A) p-p70S6K and (B) p-mTOR. HR, hazard ratio; mTOR, mammalian target of rapamycine; p, phosphorylated.
Table 3 Adjusted hazard ratios for recurrence-free interval according to PI3K and/or MAPK pathway markers in
patients who did not receive adjuvant systemic treatment
Number of cases in analysis (events) Hazard ratioa 95% confidence interval P value
p-AKT(Ser 473), (2 to 3) versus (0 to 1) 86 (27) 0.30 0.12 to 0.76 0.01
p-AKT(Thr308), positive versus negative 100 (26) 0.30 0.11 to 0.80 0.02
p-mTOR, high (≥60%) versus low (0 to 59%) 94 (26) 0.11 0.02 to 0.55 0.007
p-ERK1/2, positive versus negative 94 (26) 0.52 0.22 to 1.24 0.14
p-p70S6K, positive versus negative 94 (25) 0.11 0.04 to 0.32 <0.0001
ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase;
p, phosphorylated. aFor each marker, Cox proportional hazard models were performed with co-variables: lymph node status, age, tumor size, grade and
progesterone receptor.
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adjuvant treatment received tamoxifen only (and no aro-
matase inhibitors), while currently most ERα-positive
postmenopausal breast cancer patients receive an aroma-
tase inhibitor preceding or following tamoxifen treatment.
Since the putative predictive biomarkers studied are con-
sidered to cause escape from hormone dependency [8],
our data are thought to be applicable to current clinical
practice as well. Furthermore, the patients in our trial had
not received adjuvant chemotherapy and thereby the ob-
served effects of the putative biomarkers were not biased
by endocrine-resistant patients who were cured by adju-
vant chemotherapy. In current clinical practice, patients
who relapse despite adjuvant endocrine therapy and adju-
vant chemotherapy are both endocrine therapy resistant
and chemotherapy resistant. The adjuvant endocrine ther-
apy resistance may be explained by activation of the PI3K/
MAPK pathway and our data suggest that p-p70S6K may
identify those patients.
It would be clinically relevant to determine whether
p-p70S6K could be used as a companion diagnostic for
the addition of non-ERα-targeted drugs (like PI3K/
mTOR inhibitors) to endocrine therapy in the adjuvant
setting. In metastatic breast cancer patients, who had
been randomized between tamoxifen alone or in com-
bination with everolimus, a trend for a better treatment
efficacy was observed for patients with a tumor with
high p-p70S6K [38]. Randomized clinical trials in the
adjuvant setting testing the addition of everolimus to
hormonal therapy are currently recruiting patients
[39], and these studies are of great importance to test
the treatment predictive value of p-p70S6K in this
setting.
Conclusion
With the approval of everolimus for metastatic breast can-
cer patients with acquired endocrine therapy resistance,
the first non-ERα-targeted drug that can overcome endo-
crine therapy resistance has become clinically available.
Whether or not inhibitors of the PI3K/Akt/mTOR path-
way may overcome endocrine therapy resistance in the
adjuvant setting is currently under investigation. A bio-
marker of an activated PI3K and/or MAPK pathway with
clinical validity to predict endocrine therapy resistance in
the adjuvant setting has not been identified [10], but such
a biomarker could potentially be used as a companion
diagnostic for these non-ERα-targeted drugs. In our series
of ERα-positive postmenopausal breast cancer patients,
p-p70S6K is significantly associated with intrinsic tamo-
xifen resistance. Patients whose tumor expresses p-p70S6K,
as a marker of downstream PI3K and/or MAPK pathway
activation, have a favorable prognosis but do not benefit
from adjuvant tamoxifen. It would be of great importance
to validate these findings in other randomized series with
endocrine therapy and to further explore this marker as
a potential companion diagnostic.
p-p70S6K
p-AKT(Thr308)
p-mTOR
p-ERK1/2
p-AKT(Ser473)
0 50 100 150 200 250 300 350
Positive lymph nodes
Progesterone receptor
HER2
Grade 3
0 50 100 150 200 250 300 350
Figure 3 Unsupervised hierarchical clustering of tumor samples and corresponding expression of PI3K and/or MAPK pathway proteins.
Heat map representing unsupervised hierarchical clustering of tumor samples and corresponding expression of downstream activated proteins
in the PI3K and/or MAPK pathways from patients for whom the status of all five proteins were known (n = 350). Patients are represented horizontally.
Phosphorylated proteins are indicated vertically. Red, high/any expression of phosphorylated protein; green, no/low expression of phosphorylated
protein (dichotomization was performed according to Akaike’s information criteria). In addition the presence (red) or absence (green) of
different clinico-pathological factors is shown. ERK, extracellular signal-regulated kinase; HER2, human epidermal growth factor receptor 2;
MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase; p, phosphorylated.
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